

**Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: A
systematic review and meta-analysis of randomized clinical trials**

Mehrdad Rabiee Rad¹, Ghazal Ghasempour Dabaghi¹, Danial Habibi²

¹School of Medicine, Isfahan University of Medical Science, Isfahan, Iran


²Department of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of
Medical Science, Isfahan, Iran



















Corresponding author:

Ghazal Ghasempour Dabaghi

Email: ghasempoorghazal@gmail.com

As percentage (intention-to-treat)



	Randomisation process	Intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Ho et al.						
Olivotto et al.						
Spertus et al.						
Saberi et al.	